| 0.8 -0.029 (-3.51%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.01 | 1-year : | 1.13 |
| Resists | First : | 0.87 | Second : | 0.97 |
| Pivot price | 0.82  |
|||
| Supports | First : | 0.71 | Second : | 0.59 |
| MAs | MA(5) : | 0.79 |
MA(20) : | 0.83 |
| MA(100) : | 1.07 |
MA(250) : | 1.49 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.3 |
D(3) : | 47.6 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 3.3 | Low : | 0.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RDHL ] has closed above bottom band by 37.3%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.83 | 0.83 - 0.83 |
| Low: | 0.79 - 0.79 | 0.79 - 0.8 |
| Close: | 0.79 - 0.8 | 0.8 - 0.81 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Thu, 02 Apr 2026
RDHL Stock Price, Quote & Chart | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill
Thu, 19 Mar 2026
RedHill Biopharma (RDHL) director Tsimchi Ofer details initial share and option holdings - Stock Titan
Wed, 18 Mar 2026
[Form 3] RedHill Biopharma Ltd. Initial Statement of Beneficial Ownership - Stock Titan
Wed, 18 Mar 2026
RedHill Biopharma (NASDAQ: RDHL) CFO details ADS, RSU and option holdings - Stock Titan
Wed, 18 Mar 2026
RedHill Biopharma (NASDAQ: RDHL) CCO Scruggs files Form 3 detailing large equity stake - Stock Titan
Wed, 25 Feb 2026
Joint U.S. Commercialization of RedHill's Talicia® Commences - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 15,090 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.7 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 33 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.46 |
| Profit Margin | -97.6 % |
| Operating Margin | -107.4 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 58.5 % |
| Gross Profit (p.s.) | 1.2 |
| Sales Per Share | 1.86 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.33 |
| Price to Sales | 0.42 |
| Price to Cash Flow | -0.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|